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sion of cardiovascular calcification, including the type of
calcium-containing binder (calcium acetate is twice as effec-
tive as calcium carbonate yet contains half the amount ofTo the Editor: In their unblinded study of vascular
elemental calcium), dialysate calcium, vitamin D dose,calcification in dialysis patients, Chertow et al combine
and lipid levels. Did sevelamer-treated patients receive
results from patients receiving calcium acetate with those
a nighttime calcium supplement or increased dialysate
from patients receiving calcium carbonate. Use of these calcium to prevent hypocalcemia? Were there differences
calcium salts interchangeably in studies is not appro- in progression of calcification between calcium acetate-
priate since calcium acetate is a more potent phosphate and calcium carbonate-treated patients? Since vitamin D
binder with less calcium absorption [1]. This can be seen increases calcium absorption and hypercalcemia risk, and
in the study of Chertow et al by the differences in re- may itself predispose to cardiovascular calcification [2],
quired doses. If the hypothesis concerning the relation- Chertow et al should have controlled for vitamin D use.
ship of calcification to oral calcium advanced by the In the calcium-treated patients, low-density lipoprotein
authors is correct, it would be very useful to see the (LDL) cholesterol should have been controlled to an equiv-
study results analyzed for each salt separately in order alent level with 3-hydroxy-3-methylglutaryl coenzyme A
to test for dose response effects. This is particularly im- (HMG-CoA) reductase inhibitors. Given failure to ade-
portant because the average daily dose of calcium acetate quately control other important variables, this study by
required by patients in this study was nearly equivalent Chertow et al clearly does not establish a causal relation-
to the USRDA for calcium. ship between cardiovascular calcification and possible
It is likely that the sevelamer patients received supple- calcium loading from calcium-containing binders. We,
therefore, believe that this study by Chertow et al doesmental calcium (as shown by the absence of change in se-
not justify preferential use of the considerably more ex-rum calcium levels over the course of the year and that
pensive phosphate binder sevelamer hydrochloride. Fi-some also experienced hypercalcemia). Traditionally, in
nally, could the metabolic acidosis in this and other stud-studies of sevelamer, 1 gram of supplemental calcium is
ies be explained by an acid load provided by sevelameroften given to prevent hypocalcemia [2]. This dose is
hydrochloride [3].nearly equivalent to the calcium dose utilized by Cher-
tow et al in the calcium treatment arm. Clearly, there was
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We are grateful to the authors of these letters for theircium acetate in the treatment of hyperphosphatemia in hemodialysis
patients. Am J Kidney Dis 33:694–701, 1999 interest in our work and to the Editor for the opportunity
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to respond directly to the readership of Kidney Interna- If the investigators had not been free to modify vitamin
D dose (as well as binder dose, dialysate calcium, andtional.
“rescue” aluminum hydroxide), hypercalcemia wouldWe thank Dr. Canavese and colleagues for noting other
have been even more frequent and severe in calcium-published reports of electron beam tomography (EBT)
treated subjects. We recently confirmed that the serumin end-stage renal disease (ESRD). Vascular calcification
calcium concentration (the “tip of the iceberg”) was anis a complex process, and only some determinants of
important predictor of the magnitude of progressive cal-progressive calcification are known. These determinants
cification among calcium-treated subjects (an issue alsomay differ in ESRD and non-ESRD populations. In the
raised by Dr. Canavese and colleagues.), further support-Treat-to-Goal study, neither lipid levels nor acid-base
ing the direct adverse effect of calcium loading. Therestatus were associated with the likelihood or extent of
were no restrictions on the use of 3-hydroxy-3-methyl-progressive calcification.
glutaryl coenzyme A (HMG-CoA) reductase inhibitorsDr. Cleveland questions the validity of our results,
(“statins”) or other lipid-lowering agents in either group.specifically the “culpability of oral calcium in vascular
Dr. Fournier and colleagues also attempt to implicatecalcification” and suggests that results be presented sepa-
vitamin D in the case against calcium (an alternativerately for the acetate and carbonate salts of calcium.
suspect, if you will). Subjects treated with vitamin D at
Indeed, subjects on calcium acetate, as well as calcium study entry were likely to have had more severe second-
carbonate, experienced a statistically significant increase ary hyperparathyroidism, so that subjects on and off
in coronary and aortic calcification over the 1-year study vitamin D probably cannot be directly compared. That
period. The increase in calcification seen among calcium- being stated, we found no association between vitamin
treated subjects cannot be attributed to the provision D use and baseline coronary artery and aortic calcifica-
of vitamin D. Over the course of the study, there was tion, and no association between vitamin D use and pro-
diminished use of vitamin D in calcium-treated subjects gression of calcification over time. Moreover, vitamin D
[in response to either hypercalcemia or suppression of use diverged in the two groups over the 1-year study
intact parathyroid hormone (PTH) to below the lower period (see above). Finally, we agree that “statins” are
target limit of 150 pg/mL] and increased vitamin D use effective lipid-lowering agents and should be considered
in sevelamer-treated subjects. The dialysate calcium con- within a comprehensive program of cardiovascular dis-
centration was rarely raised. At several sites, the dialy- ease risk reduction in ESRD, along with aspirin, angio-
sate calcium concentration was reduced to below 2.5 tensin-converting enzyme inhibitors, and other agents
mEq/L in calcium-treated subjects who remained above shown to prolong life in non-uremic patients with cardio-
calcium and below PTH target ranges. vascular disease.
Drs. Nolan and Quinibi state that the design of this
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